BioDesign 2022; 10(3): 46-50
Published online September 30, 2022
© Korean Society for Structural Biology
Seung Beom Choi, Nahyeon Gu, Yu-Jeong Jang, Ui Beom Park, Tae Jun Jeong, Hyun Tae Lee and Yong-Seok Heo*
Department of Chemistry, Konkuk University, Seoul 05029, Republic of Korea
Correspondence to: *firstname.lastname@example.org
Cobolimab is an investigational antibody targeting Tim-3, an immune checkpoint protein associated with the suppression of T-cell response against cancer cells. This antibody’s safety and anti-tumor effectiveness were made clear in the clinical trial of the combination therapy using cobolimab and a PD-1 antibody. Here, the crystal structure of the cobolimab Fab in complex with an anti-kappa nanobody is determined. The crystals belonged to the space group C2221, with unit cell parameters a = 64.30, b = 119.30, and c = 184.49 Å. The structure was refined to a resolution of 2.02 Å with Rwork/Rfree = 0.197/0.233. The nanobody in the structure facilitated crystallization by restricting the elbow flexiblity of the Fab and providing extra packing interface for crystallization. This structure can be used as a model structure for predicting the protein-protein interaction between cobolimab and Tim-3.